In attempt to bypass this issue, IDH inhibitors have been added to checkpoint inhibitors and vaccine therapies to reduce the accumulation of D-2-HG and to subsequently to reverse the effect D-2-HG has on the immunity resulting in tumor volume reduction and prolonged OS [93, 94]. The gene discussed is IDH1; the disease is neoplasm.